Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics (NASDAQ:CRSP). And retail traders should know. We noticed this today when the trades showed up on publicly ...
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...
Allworth Financial LP lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,117.4% during ...
Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...
$CRSP insiders have traded $CRSP stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results